217 related articles for article (PubMed ID: 16077977)
21. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients.
Schüller J; Cassidy J; Dumont E; Roos B; Durston S; Banken L; Utoh M; Mori K; Weidekamm E; Reigner B
Cancer Chemother Pharmacol; 2000; 45(4):291-7. PubMed ID: 10755317
[TBL] [Abstract][Full Text] [Related]
22. Antitumor activity of 5'-deoxy-5-fluorouridine in human digestive organ cancer xenografts and pyrimidine nucleoside phosphorylase activity in normal and neoplastic tissues from human digestive organs.
Nio Y; Kimura H; Tsubono M; Tseng CC; Kawabata K; Masai Y; Hayashi H; Meyer C; Fukumoto M; Tobe T
Anticancer Res; 1992; 12(4):1141-6. PubMed ID: 1386969
[TBL] [Abstract][Full Text] [Related]
23. Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5[Prime]-deoxy-5-fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug.
Mata JF; García-Manteiga JM; Lostao MP; Fernández-Veledo S; Guillén-Gómez E; Larrayoz IM; Lloberas J; Casado FJ; Pastor-Anglada M
Mol Pharmacol; 2001 Jun; 59(6):1542-8. PubMed ID: 11353816
[TBL] [Abstract][Full Text] [Related]
24. Upregulation of thymidine phosphorylase in rectal cancer tissues by mitomycin C.
Ogata Y; Matono K; Sasatomi T; Ishibashi N; Torigoe S; Fukumitsu T; Mizobe T; Yamashita N; Yanagawa T; Shirouzu K
J Surg Oncol; 2006 Jan; 93(1):47-55. PubMed ID: 16353181
[TBL] [Abstract][Full Text] [Related]
25. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.
Ouchi KF; Yanagisawa M; Sekiguchi F; Tanaka Y
Cancer Chemother Pharmacol; 2006 May; 57(5):693-702. PubMed ID: 16362295
[TBL] [Abstract][Full Text] [Related]
26. Relationship between AUC of 5'-DFUR and toxicity of capecitabine, fluoropyrimidine carbamate analogs, and 5'-DFUR in monkeys, mice, and rats.
Shindoh H; Kawashima A; Shishido N; Nakano K; Kobayashi K; Horii I
J Toxicol Sci; 2006 Aug; 31(3):265-85. PubMed ID: 16960436
[TBL] [Abstract][Full Text] [Related]
27. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
[TBL] [Abstract][Full Text] [Related]
28. Role of uridine phosphorylase for antitumor activity of 5'-deoxy-5-fluorouridine.
Ishitsuka H; Miwa M; Takemoto K; Fukuoka K; Itoga A; Maruyama HB
Gan; 1980 Feb; 71(1):112-23. PubMed ID: 6445847
[TBL] [Abstract][Full Text] [Related]
29. Enhancement of antitumor activity of 5'-deoxy-5-fluorouridine (Furtulon) by taxane in human gastric cancer xenografts.
Sawada N; Nose T; Ishikawa T; Yutaka T
Oncol Rep; 2005 Jul; 14(1):53-7. PubMed ID: 15944767
[TBL] [Abstract][Full Text] [Related]
30. [Usefulness of low dose 5'-DFUR (5'-deoxy-5-fluorouridine) for advanced or recurrent breast cancer].
Sonoo H; Senoo T; Nishiki M; Morimoto T; Takashima S
Gan To Kagaku Ryoho; 1999 Jun; 26(7):951-8. PubMed ID: 10396323
[TBL] [Abstract][Full Text] [Related]
31. Antiangiogenic effect of capecitabine combined with ginsenoside Rg3 on breast cancer in mice.
Zhang Q; Kang X; Yang B; Wang J; Yang F
Cancer Biother Radiopharm; 2008 Oct; 23(5):647-53. PubMed ID: 18999937
[TBL] [Abstract][Full Text] [Related]
32. Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer.
Yoshimoto M; Takao S; Hirata M; Okamoto Y; Yamashita S; Kawaguchi Y; Takami M; Furusawa H; Morita S; Abe C; Sakamoto J
Cancer Chemother Pharmacol; 2012 Aug; 70(2):331-8. PubMed ID: 22526409
[TBL] [Abstract][Full Text] [Related]
33. [5'-Deoxy-5-fluorouridine enzymatic activation from the masked compound to 5-fluorouracil in human malignant tissues].
Hara Y
Gan To Kagaku Ryoho; 1984 Oct; 11(10):2133-43. PubMed ID: 6237613
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer.
Urien S; Rezaí K; Lokiec F
J Pharmacokinet Pharmacodyn; 2005 Dec; 32(5-6):817-33. PubMed ID: 16284918
[TBL] [Abstract][Full Text] [Related]
35. Rational design of new tumoractivated cytotoxic agents.
Verweij J
Oncology; 1999 Jul; 57 Suppl 1():9-15. PubMed ID: 10436411
[TBL] [Abstract][Full Text] [Related]
36. Lack of contribution of dihydrofluorouracil and alpha-fluoro-beta-alanine to the cytotoxicity of 5'-deoxy-5-fluorouridine on human keratinocytes.
Fischel JL; Formento P; Ciccolini J; Etienne-Grimaldi MC; Milano G
Anticancer Drugs; 2004 Nov; 15(10):969-74. PubMed ID: 15514566
[TBL] [Abstract][Full Text] [Related]
37. [A case of recurrent breast cancer with multiple lung, adrenal, inferior vena cava tumor thrombus and bone metastases successfully treated with 5'-DFUR and hormonal therapy].
Sakamoto E; Hasegawa H; Komatsu S; Hiromatsu T; Itazu K; Tabata T; Kawai K; Fukami Y
Gan To Kagaku Ryoho; 2005 Apr; 32(4):539-42. PubMed ID: 15853224
[TBL] [Abstract][Full Text] [Related]
38. [Pharmacokinetic comparison of capecitabine and 5'-deoxy-5-fluorouridine (doxifluridine; 5'-DFUR)].
Minami H; Ebi H
Gan To Kagaku Ryoho; 2005 Dec; 32(13):2053-7. PubMed ID: 16352928
[TBL] [Abstract][Full Text] [Related]
39. Comparative in vitro evaluation of transportability and toxicity of capecitabine and its metabolites in cells derived from normal human kidney and renal cancers.
Damaraju VL; Mowles D; Wilson M; Kuzma M; Cass CE; Sawyer MB
Biochem Cell Biol; 2013 Dec; 91(6):419-27. PubMed ID: 24219283
[TBL] [Abstract][Full Text] [Related]
40. [Efficacy of combination chemotherapy of cyclophosphamide and 5'-deoxy-5-fluorouridine in a mammary tumor xenograft model, MX-1].
Endo M; Fujimoto-Ouchi K; Matsumoto T; Tanaka Y; Ishitsuka H
Gan To Kagaku Ryoho; 1997 Aug; 24(10):1295-301. PubMed ID: 9279349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
